Sunshine Historical Cash Flow
| SBFM Stock | USD 2.00 0.10 4.76% |
Analysis of Sunshine Biopharma cash flow over time is an excellent tool to project Sunshine Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 19.7 M or Begin Period Cash Flow of 26.4 M as it is a great indicator of Sunshine Biopharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Sunshine Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sunshine Biopharma is a good buy for the upcoming year.
Sunshine |
About Sunshine Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Sunshine balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sunshine's non-liquid assets can be easily converted into cash.
Sunshine Biopharma Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Sunshine Biopharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Capital Expenditures is very stable compared to the past year. As of the 29th of March 2025, End Period Cash Flow is likely to grow to about 19.7 M, though Free Cash Flow is likely to grow to (8.2 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Begin Period Cash Flow | 2.0M | 21.8M | 25.1M | 26.4M | End Period Cash Flow | 21.8M | 16.3M | 18.7M | 19.7M |
Sunshine Biopharma cash flow statement Correlations
Click cells to compare fundamentals
Sunshine Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sunshine Biopharma cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 949.4K | 1.1M | 19.8M | (5.5M) | (6.4M) | (6.0M) | |
| Free Cash Flow | (658.5K) | (1.8M) | (5.6M) | (9.6M) | (8.6M) | (8.2M) | |
| Change In Working Capital | (42.6K) | (108.8K) | 3.2M | (4.4M) | (4.0M) | (3.8M) | |
| Other Cashflows From Financing Activities | (1.2K) | 3.4M | 11.1M | 7.0K | 8.1K | 7.7K | |
| Other Non Cash Items | 2.2M | 10.7M | 18.3M | 4.6M | 5.3M | 3.7M | |
| Total Cash From Operating Activities | (657.3K) | (1.8M) | (5.2M) | (8.8M) | (7.9M) | (7.5M) | |
| Net Income | (2.8M) | (12.4M) | (26.7M) | (4.5M) | (4.1M) | (4.3M) | |
| Total Cash From Financing Activities | 1.6M | 2.9M | 39.5M | 3.4M | 3.9M | 3.4M | |
| End Period Cash Flow | 989.9K | 2.0M | 21.8M | 16.3M | 18.7M | 19.7M | |
| Begin Period Cash Flow | 40.5K | 989.9K | 2.0M | 21.8M | 25.1M | 26.4M | |
| Net Borrowings | 500.9K | 416.5K | 1.6M | 2.9M | 3.3M | 3.5M | |
| Total Cashflows From Investing Activities | (13.9K) | (15.3K) | (1.2K) | (14.6M) | (13.2M) | (12.5M) | |
| Depreciation | 14.1K | 12.7K | 25.2K | 149.1K | 171.5K | 180.1K | |
| Change To Operating Activities | 8.4K | 4.1K | 1.7K | (2.9K) | (2.6K) | (2.5K) | |
| Change To Netincome | 1.2M | 2.2M | 10.7M | 18.3M | 21.1M | 22.1M | |
| Change To Account Receivables | (1.5K) | (5.9K) | (524.5K) | (594.1K) | (534.7K) | (508.0K) | |
| Investments | (1.2K) | (391.0) | (14.6M) | (15.0M) | (13.5M) | (12.8M) | |
| Change To Inventory | (7.9K) | (81.9K) | 43.0K | (2.4M) | (2.1M) | (2.0M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.